Imago Pharmaceuticals, Inc. (Imago) is a virtual, privately held company developing JNK-directed novel therapies, covered by issued Imago patents, for neurodegenerative diseases; PD, AD, SMA and for fibrotic conditions; IPF & NASH.
Imago has self-funded R&D efforts through the revenue obtained as described in the BD Approach section below.
With this revenue; supplemented by funding from Michael J. Fox Foundation, CureSMA and NIA, Imago has advanced the JNK Program up to pre-IND development activities for PD and IPF, as described in R&D Approach. SMA, AD and NASH are also under consideration as follow-on indications.
Imago is pursuing funding opportunities to advance the JNK Program into clinical trials. Options being considered include R&D collaborations and Series A Venture funding. For information send email inquiries to email@example.com.
Research & Development Approach:
Business Development Approach:
Preclinical assets purchased from Perrigo/Elan Pharmaceuticals have been sold to fund development of the JNK Program.
513,000 high-throughput compound screening library: Acquired by the DDF Chemco Limited
Parkin: Licensed to Michael J. Fox Foundation
LRRK2: Partnered with undisclosed biotech
α-Synuclein: Available for partnering or licensing
PLK2, Beta-Secretase and Gamma-Secretase: Available for licensing